The group's principal activity is to develop therapeutic products for debilitating pediatric diseases. The major products of the group include secretin for autism, ctla4-ig for stem cell transportation and uridine for mitochondrial diseases. These products are synthetic forms of naturally occurring substances that may correct improperly regulated biological processes with minimal toxicity or side effects. The customers of the group include chromatography, diagnostics, biopharmaceutical companies and laboratory researchers.
